Today, pharma companies face growing competition from generics and me-too drugs, combined with increasingly tough P&R, a clamp down on healthcare spending, and the need to treat patients for longer due to the aging population. These factors threaten both current and future revenues prompting Pharma to adopt a range of corporate strategies to respond to the changing market dynamics.

Scope

Review of key external factors impacting Pharma and shaping their strategies Analysis of steps undertaken by pharma companies to achieve cost saving and improve efficiency Assessment of corporate strategies employed by drug developers to generate new revenue growth

Highlights

Fewer drugs are gaining FDA approval year-on-year, primarily due to increasing pressure the pharmaceutical industry is facing over drug safety, fueled by several recent high-profile drug withdrawals and black box warnings. Compounded with the recent expansion of the FDA's safety powers, this will have a negative impact on Pharma's profitability. The pharmaceutical industry is facing increasingly cost-conscious times, with a declining ROI and numerous blockbuster products facing imminent generic competition. This is exacerbated by the increasing cost of licensing and M&A deals, and a harshening P&R environment. A key trend in 2007 has been the vast number of job cuts across Big Pharma in an effort to cut costs, in response to disappointing financial results driven by patent expiries of key products and resulting generic erosion. Price pressure and low reimbursement rates, which are impacting company revenues, are set to continue in 2008.

Reasons to Purchase

Identify the key trends that are impacting the industry in 2007, going forward in 2008 and beyond Understand what strategic steps pharma companies are making to maintain their profitability by cutting costs Gain insight into how Pharma are capturing new opportunities to sustain historic growth rates.